Next Phase Newsletter

A private investment firm funded by a single LP based in the Western United States invests in seed and early-stage health technology companies. The typical investment size for seed investment ranges from $250K to $1M (usually in equity or convertible notes). For early-stage companies, the firm typically co-invests with other VC firms in Series A and B financing and the investment size will depend on the company’s financial needs. The firm is geographically agnostic but prefers start-ups to be based on the West Coast. The firm is actively seeking new investment opportunities.

The firm has a focus on the digital health and informatics space, but also invests in novel therapeutics. Generally, the firm focuses on opportunities that avoid or mitigate FDA regulatory risks. The firm is agnostic in terms of subsectors and indications, but does not consider orphan indications. The firm will only consider technologies with proof of concept. Historically, the firm has invested in therapeutics that address oncology, infectious diseases, cardiovascular, and metabolic disorders; drug delivery; orthopedic devices; genomics.

The firm prefers to take a board seat but is generally flexible.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An angel group is made up healthcare professionals is seeking to invest in technologies that significantly advance the standard of care. The group considers companies at a range of stages and is geographically agnostic. Since the members are investing their own capital, the investment size and capital structure are highly flexible. The group is actively seeking new investment opportunities, and is open to leading financing rounds.

The group is interested in therapeutics, diagnostics, and medical devices. While the group will consider most any indication and technology type, the group currently has a particular interest in cell therapy and in the oncology sector. In general, the group is not interested in dermatology. The group will only consider products that have shown human clinical efficacy; in the case of therapeutics, the group generally looks at phase II companies but if a company has obtained human efficacy data in phase I, the group would consider the opportunity. 

The group invests in both private and public companies. The group performs deep scientific due diligence on all the opportunities that the group takes part in, often conducted by the group’s members.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The corporate investment arm of a Japanese biotechnology company primarily makes early stage investments solely in the Life Sciences. The firm recently raised a new fund in March 2014 and looks to make about 2-3 new investments in the next 12 months. The firm typically allocates USD 1-2 million per round and up to USD 3 million per company. The firm can invest globally, with particular interests in the USA and Europe. The firm is actively seeking new investment opportunities.

The firm seeks to invest in therapeutics, in-vitro diagnostic devices, medical devices and drug discovery platforms. For therapeutics, the firm looks for small molecules, biologics, as well as biosimilars and reformulated drugs. The firm is opportunistic in terms of indications and is particularly interested in orphan indications. The firm will consider products in all stages of development. However, the firm typically invests in products that are in pre-clinical and early-clinical. For medical devices, the firm is also opportunistic in terms of indications; however the firm is only interested in devices with a therapeutic focus.   

The firm will only co-invest with other investors in opportunities outside of Japan. For that reason, the firm prefers opportunities with a syndicate in place. The firm typically requests board observation rights in its portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The corporate venture capital arm of a United Kingdom based media and information firm is looking to make allocations into Healthcare IT. The firm focuses on information technology and media companies based in the US, Europe, and Israel. The firm can allocate up to US$10M per company, preferably in the range of $3-5M. The firm will invest at any stage of a company’s development, from early/seed stage to growth capital. The firm is actively seeking new investment opportunities.

The firm seeks to invest across the Healthcare IT sector. The firm looks for any type of company that provides data and software to healthcare and life science companies including genomics and proteomics. Historically in the life sciences, the firm invested in a bioinformatics company that provides informatics to improve speed and productivity of drug delivery.

The firm may take a board or an observer seat depending on the amount of investment. For commercial stage companies, the firm looks for companies to have a revenue run rate of $1M plus.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An evergreen life science venture fund located in Europe established 2009 and wholly owned by a Philanthropic Foundation is seeking new investments. The fund’s evergreen structure allows flexibility in the investment approach and the possibility, when appropriate, to take a long-term perspective in the investments. The fund has an annual investment capacity of approximately €50m. Investments are typically above €10-35m, and the firm prefers to take above 10% ownership. The fund invests primarily in Europe and in the USA/Canada.

The fund invests exclusively in life sciences, focusing on pharmaceuticals and medtech. For therapeutics, the firm typically prefers to invest at phase I/II but has also made investments at earlier phases of development. The fund will consider investing in medtech companies at the commercialization stage. The firm is open to opportunities in all therapeutic areas and indications.

The fund is oriented towards opportunities in the US and Europe and will take the role of lead investor in Europe. In US/Canada the firm prefers to syndicate with well-established VC investors specialized in life sciences. The fund expects to be actively in communication with management and represented on the supervisory board of portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

​A Venture Capital fund formed by a partnership between a European pharmaceutical company and US based venture capital firm is currently looking to make seed and venture stage investments into life science companies ranging anywhere from $200K to $5 million initially and up to $8 million over the life of the investment. The fund is actively seeking investment opportunities throughout the United States and Europe and could make as many as 2-4 new investments over the next year.

​The fund is focused on rare and orphan diseases that affect less than 200,000 people throughout the United States. Within this area the fund is open to therapeutics and diagnostics across a number of technology types including, antibodies, small molecules, stem cells, cell therapy, gene therapy, vaccines, molecular diagnostics, and genomics among others. The fund is interested in companies anywhere from pre-clinical through phase III of clinical trials and has no preference for platform or single asset companies. The fund is not interested in biosimilars or generics.

​The fund is looking for privately held companies with experienced management teams. The fund looks to act as a hands on investor and seeks board representation following investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A family office/venture capital firm based in New York firm manages an evergreen fund that seeks to make seed, venture, and growth equity investments in early to mid-stage medical device companies, but will also consider secured debt to help revenue generating companies with short term cash flow issues. The firm will also consider pre-seed investments. The firm can allocate anywhere from $1M to $10M per company, but generally allocates around $8M. The firm typically does 3 rounds of financing with an initial investment of around $3M. The firm is geographically agnostic, but highly prefers to invest in companies that are based in the US. The firm seeks to make about 3-4 allocations in the next 6-9 months.

The firm is currently looking for medical device companies with a strong emphasis on products with a 510(k) regulatory pathway. In terms of subsectors, the firm is looking for products specifically in the areas of interventional radiology and cardiology, spine/orthopedics and minimally invasive surgery. The firm is generally opportunistic in terms of indication.

The firm is looking to invest in companies with a management team with a track record of success in the healthcare industry. However, the firm is generally flexible and does not require a full management team. The firm can assemble the management team over the course of the investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com